HC Wainwright Predicts Spyglass Pharma FY2025 Earnings

Spyglass Pharma, Inc. (NASDAQ:SGP) – Investment analysts at HC Wainwright issued their FY2025 earnings estimates for shares of Spyglass Pharma in a report released on Tuesday, March 10th. HC Wainwright analyst Y. Chen anticipates that the company will earn ($19.06) per share for the year. HC Wainwright has a “Buy” rating and a $37.00 price target on the stock. HC Wainwright also issued estimates for Spyglass Pharma’s Q4 2025 earnings at ($6.61) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.49) EPS, Q4 2026 earnings at ($0.49) EPS and FY2026 earnings at ($2.21) EPS.

SGP has been the subject of several other reports. Stifel Nicolaus started coverage on shares of Spyglass Pharma in a research note on Tuesday, March 3rd. They set a “buy” rating and a $42.00 price objective for the company. Zacks Research upgraded Spyglass Pharma to a “hold” rating in a report on Wednesday, March 4th. Jefferies Financial Group began coverage on Spyglass Pharma in a research report on Tuesday, March 3rd. They set a “buy” rating and a $62.00 price target for the company. Wall Street Zen upgraded Spyglass Pharma to a “hold” rating in a report on Tuesday, February 17th. Finally, Leerink Partners lowered Spyglass Pharma to a “market perform” rating in a research report on Tuesday, March 3rd. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $45.00.

Spyglass Pharma Price Performance

Shares of Spyglass Pharma stock opened at $27.10 on Thursday. Spyglass Pharma has a 12-month low of $20.16 and a 12-month high of $32.44.

Insider Buying and Selling at Spyglass Pharma

In related news, Director Ra Capital Management, L.P. bought 3,690,000 shares of the business’s stock in a transaction dated Monday, February 9th. The shares were purchased at an average price of $16.00 per share, with a total value of $59,040,000.00. Following the purchase, the director owned 5,966,439 shares of the company’s stock, valued at approximately $95,463,024. This trade represents a 162.10% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Spyglass Pharma Company Profile

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).